Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral azacitidine and romidepsin in relapsed/refractory lymphoid malignancies
NCT01998035Phase 2Terminated
- Sponsor
- Columbia University
- Start
- Nov 2013
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine, romidepsin in lymphoma, Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), T-cell lymphoma, sponsored by Columbia University. Started Nov 2013; status: terminated.
02
Drugs
azacitidineromidepsin
03
Conditions
lymphomaHodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)T-cell lymphoma
Beyond the preview
Go deeper on NCT01998035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01998035.